Cite this: Xience and Promus everolimus-eluting stents get FDA approval - Medscape - Jul 03, 2008. Authors and Disclosures Shelley Wood Shelley Wood joined theheart.org as a medical journalist in ...

Abbott Laboratories' drug-coated Xience V stent prevented heart attacks and repeat surgeries more than an older artery-opening device from Boston Scientific, a study found. After a year, 4.2 ...

The Xience's success will benefit Boston Scientific to a degree, since that company's purchase of Guidant Corp. last year gave it the right to market the Xience under a different name (Promus).

In a landmark analysis capturing events occurring between 1 and 2 years, outcomes such as death/MI (2.5% vs 2.4%; P = 0.999) and TLR (2.0% vs 1.5%; P = 0.27) were still low and equivalent between the ...

BOSTON (MarketWatch) -- Abbott Laboratories said Monday that a study has shown its new drug-coated stent Xience V was associated with fewer adverse cardiac events than Boston Scientific's Taxus ...

The FDA has approved an everolimus-eluting stent for coronaries as small as 2.25 mm in diameter. The same device will be marketed by Boston Scientific and Abbott under the Promus and Xience Nano ...

The PROMUS Stentis a private-labeled XIENCE(TM) V Everolimus-Eluting Coronary Stent Systemmanufactured by Abbott and distributed by Boston Scientific under an agreementexecuted prior to the 2006 ...

Abbott Laboratories' drug-coated stent, Xience V, is significantly more effective than Boston Scientific Corp.'s Taxus three years after implantation in an artery, according to new long-term data ...

An everolimus-eluting stent with a novel platinum chromium-alloy platform is clinically noninferior to a currently available stent that releases the same drug from a cobalt chromium platform. The late ...

SAN FRANCISCO (MarketWatch) -- Abbott Laboratories said late Wednesday the Food and Drug Administration approved its Xience V drug-coated heart stent. Stents are tiny, wire mesh tubes placed into ...